AEVIS (AEVIS) H1 2025 earnings summary

Executive summary

• Achieved strong group performance in H1-2025, with consolidated gross revenue up 17.7% to CHF 621.3 million and significant EBITDA growth year-over-year, driven by strategic acquisitions and organic expansion in healthcare and hospitality.

• Integration of Spital Zofingen and CentroMedico boosted Swiss Medical Network revenue by over 20%.

• Free cash flow exceeded CHF 100 million, enabling debt reduction of over CHF 120 million.

• Strategic investments and partnerships, including Mayo Clinic Care Network and Genolier Innovation Hub, supported expansion and innovation.

• Plans to resume dividend policy in 2026, with intensified investor relations and search for strategic shareholders.

Financial highlights

• Net revenues rose 17.9% to CHF 546.0 million in H1-2025; organic growth was 2.9%.

• EBITDAR increased to CHF 104.3 million (margin 19.1%), up from CHF 87.7 million (18.9%) in H1 2024.

• EBITDA increased 24.9% to CHF 56.7 million, with margin improving to 10.4%.

• Net profit attributable to shareholders was CHF 4.2 million, compared to a loss of CHF 0.8 million in H1 2024.

• Free cash flow improved significantly, positively influenced by divestments and asset sales.

Outlook and guidance

• Expects continued organic growth and solid margins in H2 2025 across healthcare and hospitality.

• No consolidated revenue or margin targets issued for FY 2025 due to macroeconomic uncertainty.

• Plans to resume dividend policy in 2026.

• Infrastructure segment expected to benefit from positive tenant performance in year-end valuations.

• Continued focus on deleveraging and investing in value-added services.